Syremis Therapeutics

Syremis

This biopharmaceutical company develops oral small-molecule medicines for patients with schizophrenia, major depressive disorder, and other serious mental health conditions.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.

Neurosterix

This biopharmaceutical company develops allosteric modulator therapeutics to treat patients suffering from neurological and neuropsychiatric disorders, including schizophrenia and mood disorders.

LB Pharmaceuticals

This company develops oral small-molecule antipsychotic therapies for patients with schizophrenia, bipolar depression, and other neuropsychiatric disorders.

Cerevel Therapeutics

This biopharmaceutical company develops neuroscience medicines for patients with mental and neurological conditions including schizophrenia, Parkinson's disease and epilepsy.

Kynexis

This clinical-stage biotechnology company develops precision therapeutics and small-molecule inhibitors to treat cognitive impairment in patients with schizophrenia and other neurological disorders.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Autobahn Therapeutics

This company develops brain-penetrating small molecule therapies for patients with neuropsychiatric and neuroimmunologic disorders, including depression and multiple sclerosis.